Published on : Apr 15, 2015
Johnson & Johnson emerged with more than expected earnings on Tuesday, in spite of the strong opposition it faced from the rise in the dollar. The company registered its first-quarter EPS of US$1.56, comparing to US$1.54 in the same quarter the previous year, whereas the revenue declined from US$18.1 billion to US$17.4 billion. Ms. Barbara Ryan, a partner at Clermont Partners, recently was on CNBC to share her viewpoint on Johnson & Johnson and the firm’s mergers and acquisition activities.
People are a bit concerned about the strong business of Johnson & Johnson. Going forward, Johnson & Johnson will face a strong competition in Hepatitis C. There are various concerns regarding Remicade, which is around 15% of the firm’s business as it is related to several patent disputes as well as biosimilars. On the other hand, certainly, enterprises such as Pfizer and Merck in the U.S. getting advantages from the development in immune-oncology.
When Johnson & Johnson lost the proposal for Pharmacyclics, Inc. to AbbVie Inc., Ms. Barbara Ryan stated that if you look at Johnson & Johnson, it is been a huge collaboration for them, which was extremely successful medicine and AbbVie sort of stands to attain more, as they want to get into that industry.
Ryan continued stating that she think that the people are looking towards Johnson & Johnson from the outlook that they have US$20 billion capital. But they sold Cordis to focus on getting out of those with slower growth, lesser functioning margin shares of their business.